Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 127

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 127
---
 intellectual property and business needs.

21

We have sought patent protection
in the United States and various international jurisdictions related to the CER-1236 T cell technology platform and its constructs, as
well as their use as individual cellular compositions and product candidates targeting specific diseases. We also intend to seek patent
protection related to the processes and materials used in CER-1236 T cell expression as well as its use in combination therapies. As of
April 8, 2025, our patent portfolio comprises nine different patent families filed in various jurisdictions worldwide. These patent families
include two issued patents in the United States, one of which relates to CER-1236; two allowed U.S. applications, which both relate to CER-1236; nine pending U.S. applications; thirteen issued patents
in France, Germany, Italy, Spain, United Kingdom, China, Japan, Hong Kong, and Mexico; and thirty-one pending applications in Canada, China, Europe,
Hong Kong, Japan, and Korea. These patents and applications, if and when issued, are projected to expire from 2037 to 2042, absent any
available patent term adjustments or extensions. We intend to pursue, when possible, further composition, method of use, dosing, formulation,
and other patent protection directed to our current and new product candidates. We may also pursue patent protection with respect to manufacturing
and drug development processes and technology.

The following issued patents
are directed at a composition of matter and provide coverage for our CER-1236 T cell candidate:

U.S. Patent No. 11,708,423,
having an anticipated expiration date of March 26, 2039, including 186 days of patent term adjustment awarded by the USPTO;

EP Patent No. 3,519,441 (validated
in the United Kingdom, France, Spain, Germany, and Italy), having an anticipated expiration date of September 26, 2037, absent any available
patent term adjustments or extensions;

JP Patent No. 7286658 having
an anticipated expiration date of September 21, 2038, absent any available patent term adjustments or extensions; and

CN Patent No. ZL201880076426.1
having an anticipated expiration date of September 21, 2038, absent any available patent term adjustments or extensions.

Competition

The biotechnology and pharmaceutical
industries have made substantial investments in recent years into the rapid development of novel immunotherapies for